Kornimate/medical-research-clean huggingface dataset:
alveolar macrophage proteomics in hiv-associated emphysema

Conditions: HIV; Emphysema; HIV Infections

Summary: this study is being done to examine lung function changes in individuals with hiv infection and to understand why individuals with hiv have increased risk of lung damage from cigarette smoking.

to delineate the natural history of hiv associated emphysema in the haart era. to compare the alveolar macrophage proteomes from hiv-seropositive smokers with emphysema to the alveolar macrophages proteomes of both hiv+ smokers without emphysema and hiv- smokers. to establish whether coinfection with hiv and hepatitis c results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.

Eligibility criteria:
inclusion criteria: * clinically stable hiv-seropositive (and hiv-seronegative) individuals * ages 18 years and older * female subjects on no oral contraception with a negative pregnancy test * subjects capable of giving written consent exclusion criteria: * known medical illness that would preclude bronchoscopy/bal (e.g. unstable angina, new cardiac arrhythmia). this only pertains to subjects involved in the bronchoscopy phase of the study. * pregnant females * prisoners

Keywords: lung damage cigarette smoking hiv-seropositive emphysema
enflow iv fluid and blood warming system

Conditions: Hypothermia; Anesthesia

Summary: this study is part of a post-market clinical follow-up (pmcf). the purpose of this study is to verify in a routine clinical environment with a number of caregivers and subjects that the enflow performs as intended when used as an element of maintaining acceptable core temperatures.

eligible subjects from the study will be recruited from patients with scheduled surgeries. after being informed about the study and potential risks, patients given informed consent will undergo scheduled surgery with the use of enflow iv fluid and blood warming system. the following temperature measurements will be collected during surgery: * baseline temperature measurement (0-15 minutes prior to induction) * induction temperature measurements (15 minutes, 30 minutes, 60 minutes, 90 minute post-induction) * continued temperature measurements (every 30 minutes, plus end of surgery) * or ambient temperature at induction and end of surgery. temperature will be measured and collected post-surgery upon arrival to the pacu and 30 minutes post-arrival.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * patients requiring surgery expected to last at least 1 hour. * expectation of the perioperative need for at least one liter of infused fluids warmed during infusion * informed consent exclusion criteria: * recent history of fever (\>38 c, within 24 hours of surgery) * active infection * pregnant women * terminal illness (\<30 days) * intended use of cardiopulmonary bypass * clinical intention for perioperative cooling and hypothermia * unavailability of esophageal measurement during surgery * attending physician does not believe participation of the patient is in their best interest.

Keywords: surgery
add-on effects of valsartan on morbi- mortality (kyoto heart study)

Conditions: Hypertension; Ischemic Heart Disease; Congestive Heart Failure; Stroke

Summary: the kyoto heart study is to assess the add-on effect of valsartan, an angiotensin-receptor blocker, on top of the conventional treatment in high risk patients in japan with hypertension in terms of the morbidity and mortality.

although many reports show that ace inhibitors and angiotensin ii receptor blockers (arb) are superior for prevention of cardiovascular events, previous data are not enough for the patients who have more than one risk factor and for anti-atherosclerotic effects of arb. in japan, there were only a few large-scale trials for cardiovascular disease prevention, and it has not been clarified whether the evidence in western countries could be unqualifiedly applied to japanese patients as a long-range strategy. the kyoto heart study is to assess the add-on effect of valsartan, an angiotensin-receptor blocker, on top of the conventional treatment in high risk patients with hypertension in terms of the morbidity and mortality.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypertension * clinical diagnosis of one or more risk factors, such as diabetes, smoking habit, lipid metabolism abnormality, history of ischemic heart disease (ihd) or cerebrovascular disease, obesity (bmi\>25), chronic heart failure (nyha ii-iii), and electrocardiogram (ecg) abnormality (lvh) exclusion criteria: * patients who have already been administered arb * patients with ihd within 6 months after percutaneous coronary intervention(pci), and who are stable but are going to implement pci or coronary artery bypass grafting(cabg) * severe/malignant/secondary hypertensive patients * pregnant women and women of childbearing potential * history of heart failure, unstable angina, myocardial infarction, ptca, or cabg within the preceding 6 months * arrhythmia needed to be treated or accompanied with symptoms, second or third degree av block * severe renal impairment (serum creatinine \>3.0 mg/dl) * severe hepatic impairment (hepatic failure, cirrhosis, etc.)

Keywords: high risk hypertension ischemic heart disease angiotensin receptor blockers cardiovascular mortality- morbidity kyoto heart study
the efficacy of the traditional chinese medicine fangji huangqi pill combined with mobic on active knee osteoarthritis

Conditions: Fangji Huangqi Pill; Knee Osteoarthritis

Summary: knee osteoarthritis (koa) is known as degenerative joint disease, which is the most common form of arthritis and the leading cause of disability, loss of function and pain worldwide. effective therapy to manage ra is still lack at present. fangji huangqi pill (fhp) is a chinese medicine which has been widely used in treating koa in china for hundreds of years to relieve pain, reduce swelling and protect the affected joints from further degeneration. however, no certain evidence to show the effect of fhp for the management of active koa.

a randomized, double-blind, placebo-controlled clinical trials (rct) will be conducted to explore whether the fhp could relieve pain and protect joints. 200 participants suffering from koa will be enrolled and treated with fhp or placebo for 1 month. the primary outcome measures are the visual analogue scale (vas), western ontario and mcmaster university of orthopedic index (womac), the lequesne index, and mos sleep scale would be measured from the baseline to 1 month. the second outcome measures would be the six minutes walking test, the short form 36-item health survey (sf- 36), the x-ray of both knees, and the adverse events from the baseline to 2 weeks, 4 weeks, and 12 weeks' follow-up. in addition, the vas score, the womac score, the lequesne index, and ais sleep scale from the baseline to 2 weeks and 12 weeks' follow-up are also the second outcome measures.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for knee osteoarthritis (american college of rheumatology criteria) * grade 0-3 on the kellgren-lawrence grading system * no serious medical history * no known drug allergies * no steroids, glucosamine, chondroitin sulfate, sodium hyaluronate before fangji huangqi pill treatment within 1 month exclusion criteria: * combined with other disease such as rheumatoid arthritis, lupus arthritis and et. al * grade 4 on the kellgren-lawrence grading system * allergy to study drug * participating in other clinical trial * unwilling to give informed consent
paradigm i clinical trial: study of the pfx closure system in subjects with cryptogenic stroke, transient ischemia attack or paradoxical embolism

Conditions: Patent Foramen Ovale

Summary: the primary objective of this study is to demonstrate the safety of the pfx closure system when utilized for patients with patent foramen ovale (pfo) suffering from cryptogenic stroke, transient ischemic attacks or paradoxical embolism.

patent foramen ovale has been implicated in the etiology of paradoxical embolism, cryptogenic stroke, transient ischemic attack (tia), and right to left gas embolism in severe decompression illness. an association between patent foramen ovale and severe migraine headaches has also been reported. several implantable devices are being used for percutaneous closure of patent foramen ovale; we propose to use a non-implantable system to safely effect closure.

Eligibility criteria:
inclusion criteria: * subject is between 18 and 65 years old. * documented patent foramen ovale as determined by positive micro bubble study demonstrating right to left shunt and/or anatomic detection and functional assessment by pre-operative tcd and peri-operative echocardiography or ultrasound. * subjects with a history of cryptogenic stroke, transient ischemic attack or paradoxical embolism due to presumed paradoxical embolism through a pfo. * negative pregnancy test in women who are of child-bearing potential. * signed informed consent form. exclusion criteria: * presence of thrombus at the intended site of closure, in left atrial appendage, or documented evidence of venous thrombus in the vessels through which access to the pfo is gained. * active endocarditis, or other infections producing a bacteremia. * presence of atrial septal defects or fenestrations which allow right-to-left shunting. * presence of implanted cardiac valves, pacemaker, implantable cardioverters/defibrillators (icds) or vena cava filters. * subjects with an intra-cardiac mass, tumor, clot or vegetation. * large, redundant atrial septal aneurysm that would prohibit adequate device access to the pfo or closure of the pfo, in the judgment of the investigator. a coexisting redundant atrial septal aneurysm is considered large if it prohibits the ability of the operator to adequately achieve vacuum suction necessary to achieve pfo closure. * presence of arrhythmia requiring pharmacologic or electrical therapy intervention or 1st degree block. * current enrollment in any investigational trial(s) using devices implanted in the vascular system or enrolled in any experimental drug study(ies) within three months of study entry. * history of stroke or tia within the past 14 days. * source of stroke other than paradoxical embolization. * hemodynamic instability or shock. * hypercoagulable disorder. * subjects with coagulation disorders who are unable to take antiplatelet or anticoagulant therapy.
avatar therapy in comparison to cognitive behavioral therapy for treatment-resistant schizophrenia

Conditions: Auditory Hallucination, Verbal; Treatment-resistant Schizophrenia

Summary: schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society. unfortunately, 25-30% of schizophrenia patients respond poorly to antipsychotic medication. moreover, psychotherapeutic treatment alternatives are very limited for this suffering population. this unmet clinical need requires innovation and action. psychotherapeutic treatment alternatives such as cognitive behavior therapy (cbt) provide at best moderate results. using immersive virtual reality, we recently tested a novel psychotherapeutic intervention, avatar therapy (at), where the therapist engages in a dialogue with the patient through a virtual representation of the patient's distressing voice. this approach, being both relational and experiential, provides a unique opportunity to aid patients gain control over their voice. the results of our pilot study on at were clinically promising for the severity and distress related to hallucinations, positive symptomatology and emotion regulation. to further research in this field, the primary goal of this randomized-controlled, single-site parallel study is to show that at is superior to cbt for the treatment of persistent auditory hallucinations in schizophrenia. our secondary goal is to examine the effects of these interventions on emotion regulation, mood symptoms (anxiety and depression), self-esteem, level of functioning and quality of life.


Eligibility criteria:
inclusion criteria: * distressing auditory verbal hallucinations * medication resistance relating to auditory verbal hallucinations (no response after 3 antipsychotics trials lasting at least 4 weeks each with a minimum of 400mg chlorpromazine equivalent) * dsm-5 diagnosis of schizophrenia or schizoaffective disorder exclusion criteria: * any change in medication within the past 2 months; * substance use disorder within the last 12 months * neurological disorder or unstable and serious physical illness * ongoing psychotic episode * cognitive behavioral therapy for psychosis within the last 12 months

Keywords: auditory verbal hallucinations schizophrenia treatment-resistant psychotherapy cognitive behavioral therapy avatar therapy virtual reality
effectiveness of virtual reality vision therapy - verve

Conditions: Convergence Insufficiency

Summary: the purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. we will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. the virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. we will compare the results of a participant before and after playing the video game.


Eligibility criteria:
inclusion criteria: * age 9 years and older * ciss score ≥ 16 * best-corrected distance visual acuity of 20/25 or better in each eye * random dot stereopsis appreciation of 500 seconds of arc or better * parent or subject understands the protocol and is willing to enroll in the study exclusion criteria: * constant strabismus at distance or near * vertical heterophoria ≥ 2 ∆ at distance or near * ≥ 2 line interocular difference in best-corrected visual acuity * near point of accommodation \> 20 cm in either eye as measured by push-up method * manifest or latent nystagmus * non-strabismic binocular vision and accommodative disorders associated with known disease of the brain * diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, graves orbitopathy, myasthenia gravis, diabetes mellitus, parkinson disease * any ocular or systemic medication known to affect accommodation or vergence such as anti-anxiety agents (e.g., librium or valium), anti-arrhythmic agents (e.g., cifenline, cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g., propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., compazine, mellaril, thorazine), tricyclic antidepressants (e.g., elavil, nortriptyline, tofranil) * inability to comprehend and/or perform any study-related test or procedure
development and validation of the prediction model for functional mitral regurgitation regression in heart failure patients taking guideline-directed medical therapy

Conditions: Mitral Regurgitation; Heart Failure

Summary: this observational study is to develop and validate the prediction model for functional mitral regurgitation regression in heart failure patients taking gdmt. the patients diagnosed ≥2+ functional mitral regurgitation by ultrasonic cardiogram are enrolled in this study and would be clinically followed by at least one year (clinical visit at 3 months, 6 months, and 12 months), and then by when the endpoints are reached.


Eligibility criteria:
inclusion criteria: * age\>18 years old * ≥2+ fmr * receiving gdmt exclusion criteria: * degenerative mitral regurgitation * myocardial infarction, percutaneous coronary intervention, coronary bypass grafting surgery, cardiac resynchronization therapy, or stroke within three months prior to this study * ≥2+ aortic stenosis or regurgitation * previous surgical mitral valve repair or replacement * restrictive cardiomyopthy, hypertrophic cardiomyopathy, or constrictive pericarditis * severe heart failure (nyha class iv) or left ventricular ejection fraction \< 20% * symptomatic hypotension affecting gdmt prescription * severe hepatic or renal insufficiency * life expectancy \< 12 months * pregnancy
full early atrial diagnostics in single chamber icd patients using the dx lead and home monitoring in brazil.

Conditions: Arrhythmias, Cardiac

Summary: to demonstrate the value and benefits of biotronik's exclusive dx technology in assessing the incidence of supraventricular arrhythmias, mainly atrial fibrillation (af), in patients with an indication for single chamber icds. effects of the dx technology on related events, such as delivery of therapies and medical management, including eventual complications. extended benefits offered by dx devices when associated with daily remote monitoring, by means of biotronik's home monitoring service center (hmsc).

to demonstrate the value and benefits of biotronik's exclusive dx technology in assessing the incidence of supraventricular arrhythmias, mainly atrial fibrillation (af), in patients with an indication for single chamber icds. effects of the dx technology on related events, such as delivery of therapies and medical management, including eventual complications. extended benefits offered by dx devices when associated with daily remote monitoring, by means of biotronik's home monitoring service center (hmsc). primary endpoint: - first confirmed episode of af or atrial flutter (afl) or supraventricular tachycardia (svt), detected and transmitted to the hmsc. other events of interest: * rate of successful transmissions received and stored on the hmsc platform; * hospital admissions related to cardiologic outcomes, at any time throughout the fu period; * a composite outcome of any of the following device-related complications: need for any lead repositioning or replacement, pneumothorax, new pericardial effusion, tamponade, procedure-related death or wound infection, within 60 days after the icd insertion.

Eligibility criteria:
inclusion criteria: 1. indication for implanting of a single chamber icd (primary or secondary prevention) according to current guidelines; 2. sustained sinus rhythm as the current prevalent atrial rhythm; 3. planned de novo implantation with a biotronik single chamber dx icd system; 4. patient is able to understand the nature of study and to provide written informed consent; 5. patient is willing and able to perform all follow up visits at the study site; 6. patient is willing and able to use the cardiomessenger and accepts the biotronik home monitoring concept. exclusion criteria: 1. age \< 18 years 2. any limitation to contractual capability; 3. female patients who are pregnant or breast feeding or planning pregnancy during the course of the study; 4. known active malignant disease or recovered from malignant disease within 2 years prior to enrollment; 5. life expectancy \< 2 years; 6. patient is participating in any other interventional clinical investigation.
novosyn® quick in patients undergoing episiotomy closure

Conditions: Episiotomy Wound

Summary: retrospective, monocentric clinical study on the clinical performance of novosyn® quick in patients undergoing episiotomy closure.

the study design is a retrospective, consecutive series of women with a spontaneous vaginal delivery who required an indicated episiotomy with novosyn® quick between the period january 2020 - december 2020 at hospital general de catalunya. all women treated with novosyn® quick between january 2020 - december 2020 at the hospital general de catalunya will be analyzed. the investigator team will access medical records for the cohort of patients identified.

Eligibility criteria:
inclusion criteria: * women who underwent an indicated episiotomy between january 2020 - december 2020 at the hospital general de catalunya (sant cugat del vallès, spain) and received novosyn® quick exclusion criteria: * no exclusion criteria have been set
glottic visualisation during laryngoscopy

Conditions: Intubation

Summary: in this study, we aimed to investigate the effects of head and neck positions on the visualization of glottis and the success of intubation during videolaryngoscopy in obese patients.

tree different head and neck positions will compare for glottic visualization and intubation success rates in obese patients (bmi\> 30 kg / m2) who required endotracheal intubation for general anesthesia between 18-65 years of age.

Eligibility criteria:
inclusion criteria: * being 18-65 aged * being obese * undergoing surgery under general anesthesia exclusion criteria: * having difficult airway * being american society of anesthesiologist (asa) 4 physical status * undergoing emergency surgery
preemptive pharmacogenetic-guided metoprolol management for postoperativeatrial fibrillation in cardiac surgery

Conditions: Post-operative Atrial Fibrillation

Summary: metoprolol is frequently administered to cardiac surgery patients to reduce the incidence of postoperative atrial fibrillation (poaf). metoprolol is metabolized by the enzyme cyp2d6, which is known to have many mutations that could influence a patient's ability to metabolize the drug. in this prospective clinical trial, the investigators will determine the genotype of cyp2d6 for patients undergoing cardiac surgery, provide an altered dosing recommendation for metoprolol, then report the relative effectiveness in managing poaf for each pharmacogenetic- guided dosing category. the investigators will also explore the effects of personalized metoprolol dosing recommendations on outcomes in hospital length of stay, cost, and provider participation.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * scheduled for surgical procedure (coronary artery bypass graft and/or valve repair/replacement) at vanderbilt university medical center exclusion criteria: * history of allergic reactions or contraindications to beta-blockers * patients with persistent atrial fibrillation

Keywords: metoprolol genotype phenotype cyp2d6
to evaluate the efficacy and safety of js002 in hofh patients

Conditions: Hyperlipemia

Summary: js002 is a recombinant human anti-pcsk9 monoclonal antibody. this phase ii open-label, single-arm study aims to evaluate the efficacy and safety of js002 in patients with homozygous familial hypercholesterolemia a dose group (450 mg) was set up in this study.thirty subjects are planned to be enrolled. each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.


Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. age ≥12 and ≤75 years old; 3. weight ≥40kg at the time of screening 4. patients diagnosed with hofh 5. low-density lipoprotein cholesterol (ldl-c) level ≥3.4mmol/l at the time of screening 6. fasting triglycerides ≤4.5 mmol/l; exclusion criteria: 1. history of nyha class iii-iv heart failure or ef\<30% 2. history of uncontrolled arrhythmia within 3 months 3. history of mi,ua, pci or cabg, stroke within 3 months. 4. history of dvt or pulmonary embolism within 3 months. 5. planned cardiac surgery or revascularization. 6. uncontrolled hypertension. 7. uncontrolled diabetes mellitius (hba1c\>8.0%）. 8. other conditions that the researchers considered inappropriate to participate in the study.